SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across i ...

An updated edition of the Jan. 6, 2026, article.Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.It is important to distinguish between genetics and genomics. Genetics focuses on individual genes and their functions, whereas genomics primarily ai ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research and product offerings, particularly in the context of AI and automation [15][16].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Suzhou Leadsynbio Technology Co., Ltd. 蘇州引航生物科技股份有限公司 (the "Company") (A joint stock company incorporated in the Pe ...

Core Thesis - Twist Bioscience Corporation is positioned as a leader in synthetic biology and next-generation genomics, with a strong growth trajectory and potential for re-rating in the market [1][4]. Company Overview - Twist Bioscience manufactures synthetic DNA-based products using a unique silicon-based DNA synthesis technology, enabling high-precision and high-throughput manufacturing [2]. - The company's offerings include synthetic DNA, gene fragments, next-generation sequencing tools, and a growing biopharma business focused on antibody discovery and humanized transgenic mouse models [2]. Customer Adoption and Financial Performance - Customer adoption has increased to approximately 2,484, up from 2,300 a year earlier, supported by collaborations with partners like Element Biosciences and Ginkgo Bioworks [3]. - For Q3 2025, revenue reached $96.1 million, an 18% year-over-year increase, driven by growth in synthetic biology ($35.2 million), next-generation sequencing ($55.3 million), and biopharma ($5.6 million) [3]. - Gross margin was reported at 53.4%, leading to a net income of $20.4 million and adjusted EBITDA of $8 million [3]. Financial Outlook - The company projects full-year revenue between $374 million and $376 million, with expectations for adjusted EBITDA breakeven by fiscal 2026 [4]. - Twist has a solid balance sheet with $250.8 million in cash and $478.2 million in equity, indicating a strong financial position [4]. - Despite a market cap of $1.6 billion and a share price of $26.33, the current valuation reflects caution rather than the company's strengths, suggesting potential for future growth [4].

Core Viewpoint - The Chinese synthetic biology manufacturing industry is experiencing rapid growth, with projections indicating a market size approaching 800 billion yuan in 2024 and nearly 1 trillion yuan in 2025, reflecting a growth rate of 26.2% from 2024. The industry is expected to exceed 1 trillion yuan by 2026 and reach 1,703.7 billion yuan by 2027, driven by policy incentives and technological breakthroughs [2]. Industry Overview - The primary focus of the Chinese synthetic biology manufacturing sector is on biopharmaceutical products, which are projected to reach a market size of 334.3 billion yuan in 2024, accounting for 42.9% of the total industry. The demand for biopharmaceuticals is expected to increase due to the ongoing development of new therapies such as cell and gene therapies [3]. Regional Distribution - The synthetic biology manufacturing industry in China exhibits a "three-legged" structure, with significant contributions from East China, North China, and Central South China. By the first half of 2025, these three regions are expected to collectively exceed 700 billion yuan, with East China leading at 311.5 billion yuan, supported by favorable policies and industrial collaboration [4]. Industry Chain Structure - The synthetic biology manufacturing industry chain consists of upstream raw material supply, midstream product processing, and downstream terminal sales applications. Upstream includes various biomass raw materials and biomanufacturing equipment. Midstream encompasses biopharmaceuticals, bio-foods, agricultural bio-products, bio-based materials, and biofuels. Downstream involves terminal sales and applications in healthcare, agriculture, environmental protection, and daily chemicals [7].

Industry Overview - Genomics is a comprehensive study of genomes, which has gained significant interest from pharmaceutical and biotechnology companies for understanding diseases and developing therapies [2] - The distinction between genetics and genomics is crucial, with genomics focusing on the complete set of genes and their interactions within an organism [3] - Insights from genomic research are increasingly utilized to evaluate patient responses to drugs and support the development of targeted therapies, advancing personalized medicine [4] - The growth of genomics has also bolstered synthetic biology, which applies engineering principles to biology for various applications, including drug discovery and gene editing [5] - The rapid advancements in genomics are driven by significant reductions in the cost and time required for genome sequencing [6] Market Projections - The genomics market is projected to reach $80.17 billion by 2032 [9] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to grow at a CAGR of 17.7% from 2026 to 2033 [9] Key Companies - **Pacific Biosciences of California (PACB)**: Specializes in advanced long-read sequencing systems for various applications, including healthcare and agriculture. The company has a Zacks Rank 2 (Buy) [12][14] - **Wave Life Sciences (WVE)**: A clinical-stage biotechnology company focusing on RNA medicines. The company reported positive interim data for its obesity treatment candidate WVE-007, which showed improvements in body composition [15][17] - **Sana Biotechnology (SANA)**: Developing cell engineering platforms for diseases like type 1 diabetes and B-cell cancers. The company has suspended its CAR T programs to focus on more promising candidates and has a Zacks Rank 3 [19][21]

Core Insights - Twist Biosciences Corporation is highlighted as one of the most promising gene editing stocks according to analysts, with recent price target increases reflecting confidence in its performance [1][2]. Company Overview - Twist Bioscience (NASDAQ: TWST) is a biotechnology company that has developed a proprietary silicon-based DNA synthesis platform, which is essential for modern genetic research and engineering [4]. Analyst Ratings and Price Targets - Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight rating, indicating confidence in the company's margin progress and expected performance in the life sciences tools sector [1]. - Stephens initiated coverage on TWST with an Overweight rating and a price target of $41, citing the company's proprietary technology as a competitive advantage in synthetic biology and research markets [2]. Product Developments - On December 4, 2025, Twist Bioscience launched research-grade Plasmid DNA Preps aimed at supporting pre-clinical nucleic acid therapeutics research, enhancing its role as a supplier for biotech and pharmaceutical discovery workflows [3].

Core Insights - Ginkgo Bioworks has partnered with Carnegie-Mellon University for the POSEIDON program, aimed at early cancer detection and intervention, supported by funding from ARPA-H [1][2] Group 1: Partnership and Project Overview - The partnership involves Ginkgo Bioworks as the Commercial Partner, with the project led by Rebecca Taylor from Carnegie Mellon University [1] - The project aims to develop an innovative orally administered pill with tumor-targeting sensors and a user-friendly at-home cancer screening device [2] Group 2: Technology and Innovation - The pill will utilize synthetic biology and nucleic acid nanotechnology to detect tumor-specific conditions such as low oxygen, acidity, and lactate, which are indicators of cancer [3] - The sensors will release reporters to indicate tumor presence and its tissue of origin, with results collected through urine [3] Group 3: Project Goals and Impact - The dual-function approach aims to provide high precision in detecting hidden tumors, potentially transforming early cancer diagnostics [4] - The project includes a multidisciplinary team from various academic institutions and corporate partners, emphasizing the importance of interdisciplinary collaboration in developing new diagnostics [4]

Industry Trends & Competitive Landscape - Biotech industry experienced a boom, but America's lead is slipping as China prioritizes synthetic biology [1] - Urgent need for strong American presence and young American leaders in the next generation of biotechnology [2] Scientific Advancements & Potential Breakthroughs - Lambert's project has the potential to be a major scientific breakthrough if further testing is successful [3] - A better diagnostic for Lyme disease has been developed, applicable beyond Lyme disease [3] Technology & Delivery Methods - Lipid nanoparticles are being considered as a delivery method [2]